Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...

Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.

Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...

Vertex Pharmaceuticals (VRTX ... suggest that it may perform in line with the broader market in the near term. History suggests their performance could be sensational. From 2012 (when our Director ...

Vertex Pharmaceuticals (VRTX ... to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988.

Vertex Pharmaceuticals Inc. closed $106.51 short of its 52-week high ($519.88), which the company reached on November 8th.

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...

However, this doesn't mean you can't have strong opinions about certain investments. I'm quite confident that some stocks will be winners over the long run. Here are my three highest-conviction growth ...

The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $402.49, representing a -1.13% change from its previous close.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 10:30 AM ETCompany ParticipantsDr.